Randomized, Double-Blind Placebo-Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects with Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging

Sponsor: Quintiles, Inc

Location(s): United States


The purpose of this study is to evaluate the effect of MLN1202 on arterial inflammation in participants with stable atherosclerotic cardiovascular disease (CVD) who are receiving standard-of-care (SOC) therapy.